Isoliquiritigenin Inhibits Oral Squamous Cell Carcinoma and Overcomes Chemoresistance by Destruction of Survivin
- 1 January 2023
- journal article
- research article
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 51 (08) , 2221-2241
Abstract
The oncoprotein survivin plays a pivotal role in controlling cell division and preventing apoptosis by inhibiting caspase activation. Its significant contribution to tumorigenesis and therapeutic resistance has been well established. Isoliquiritigenin (ISL), a natural compound, has been recognized for its powerful inhibitory effects against various tumors. However, whether ISL exerts regulatory effects on survivin and its underlying mechanism in oral squamous cell carcinoma (OSCC) remains unclear. Here, we found that ISL inhibited the viability and colony formation of OSCC, and promoted their apoptosis. The immunoblotting data showed that ISL treatment significantly decreased survivin expression. Mechanistically, ISL suppressed survivin phosphorylation on Thr34 by deregulating Akt-Wee1-CDK1 signaling, which facilitated survivin for ubiquitination degradation. ISL inhibited CAL27 tumor growth and decreased p-Akt and survivin expression in vivo. Meanwhile, survivin overexpression caused cisplatin resistance of OSCC cells. ISL alone or combined with cisplatin overcame chemoresistance in OSCC cells. Overall, our results revealed that ISL exerted potent inhibitory effects via inducing Akt-dependent survivin ubiquitination in OSCC cells.Keywords
Funding Information
- The National Natural Science Foundation of China (81904262)
- the Natural Science Foundation of Hunan Province (2022JJ30630)
- the Hunan Provincial Department of Education (22A0249)
- the Health Commission of Hunan Province (202108051626)
- the Department of Science and Technology of Hunan Province (2021SK53301)
- the Key Research Project of Hunan Province (2020SK2137)
- The Natural Science Foundation of Changsha (kq2208458)
This publication has 61 references indexed in Scilit:
- Enhanced expression of Survivin has distinct roles in adipocyte homeostasisCell Death & Disease, 2017
- A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing non-small-cell lung cancer cellsCell Death & Disease, 2014
- Loss of Survivin influences liver regeneration and is associated with impaired Aurora B functionCell Death & Differentiation, 2013
- An essential role for the Id1/PI3K/Akt/NFkB/survivin signalling pathway in promoting the proliferation of endothelial progenitor cells in vitroMolecular and Cellular Biochemistry, 2011
- Terameprocol (Tetra-O-Methyl Nordihydroguaiaretic Acid), an Inhibitor of Sp1-Mediated Survivin Transcription, Induces Radiosensitization in Non-small Cell Lung CarcinomaJournal of Thoracic Oncology, 2011
- GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cellsCancer Biology & Therapy, 2010
- Endogenous Tumor Suppression Mediated by PTEN Involves Survivin Gene SilencingCancer Research, 2009
- Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of SurvivinJournal of Clinical Oncology, 2008
- Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer TherapeuticsClinical Cancer Research, 2008
- Survivin: Role in Diagnosis, Prognosis, and Treatment of Bladder CancerAdvances in Anatomic Pathology, 2006